Ovecure

Ovecure is a South Korean biotechnology company specializing in the development of next-generation multi-specific antibody therapeutics. The company utilizes its proprietary Ove-body (Optimized and Versatile Engineered antibody) platform to design antibodies that can simultaneously bind to multiple targets, enhancing therapeutic efficacy and reducing side effects. Their primary focus areas include oncology and immunology, with a pipeline of candidates aimed at treating various solid tumors and inflammatory conditions. Ovecure was founded by Professor Yong-Sung Kim of Ajou University, a prominent figure in antibody engineering. The company's lead program, OVC-101, is a bispecific T-cell engager designed to treat solid tumors by targeting PD-L1 and CD3. Ovecure has secured significant venture capital funding, including a Series A round, to advance its innovative platform and clinical candidates.